
FOXG1 RESEARCH FOUNDATION
DEDICATED TO CURE FOXG1 SYNDROME
The FOXG1 Research Foundation (FRF) is the leading global organization accelerating research to cure FOXG1 syndrome and related neurological disorders.
We are running industry-level translational science across genetic therapies and drug screens.
We created the largest library of FOXG1 animal models, cell lines, and patient natural history data.
We understand the FOXG1 gene and patient symptoms at the deepest levels.
We are the only organization focused on FOXG1 science, FOXG1 patient data, and the FOXG1 patient and clinician community.
We serve the FOXG1 community through resources, clinician guides, conferences, caregiver networking, advocacy, and love.
We are committed to every FOXG1 patient in the world.
Science * Patients * Community
What is FOXG1 Syndrome?
FOXG1 syndrome is a rare neurological genetic disorder that greatly impacts brain development and typically causes epilepsy and physical and cognitive disabilities. Most children with FOXG1 syndrome cannot walk or talk or take care of their basic needs. Mutations to the FOXG1 gene are mostly non-inherited (de-novo). There are currently about 1000 known people in the world diagnosed with FOXG1 syndrome. There are no treatments for FOXG1 syndrome, yet. We are here to change that.
FOXG1 is a critical transcription factor gene that is linked to many related brain disorders and scientists believe that FOXG1 holds the key to unlocking brain disorders affecting millions of people, including autism, Alzheimer's, schizophrenia, epilepsy, brain cancers, and more.
Our Scientific Advisory Board
Orrin Devinsky, MD
Neurosurgeon, NYU Langone, Chief of Service, NYU Epilepsy
Robin Kleiman, Ph.D
Senior Director, Biogen Research Associate, Boston Children’s Hospital
Kiran Reddy, MD
Blackstone Life Sciences, Former CEO Praxis
Aris Economides, PhD
Vice President of Research, Regeneron Pharmaceuticals
Dr Scott Dindot, PhD
Assistant Professor, Texas A&M College of Medicine
Ingrid Scheffer, MD, PhD
Neurologist and Senior Research Fellow, Florey Institute of Neuroscience and Mental Health
Elli Brimble, MSc, MS, CGC
Geneticist, Lucille Packard Children’s Hospital at Stanford
Justin To
Chief Operating Officer of BridgeBio Gene Therapy
Heather Olson, MD, MS
Neurologist, Boston Children's; Neurology Instructor, Harvard Medical
Xilma Ortiz-Gonzalez, MD, PhD
Pediatric Neurologist, CHOP, Neurology Instructor, University of Pennsylva
Adam James Waite, PhD
Scientist, Calico Life Sciences, LLC
Gordon Fishell, PhD
Scientist, Broad Institute; Professor, Harvard Medical School
Rodney Samaco Assistant Professor of Molecular and Human Genetics at Baylor College of Medicine
Toni Cathomen, PhD
Director, Institute for Cell and Gene Therapy, University of Freiburg
Ritu Lal, PhD
Clinical Pharmacology Consultant
Mark Pykett, PhD
Chief Innovation Officer, PTC Therapeutics, former CEO, Agilis Biotherapeutics
Dr Nadia Bahi-Buisson, MD, PhD
Pediatric Neurology, Necker Enfants Malades University Hospital, Paris